FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients switching from sodium phenylbutyrate to RAVICTI should receive the dosage of RAVICTI that contains the same amount of phenylbutyric acid.
Danish: Patienter, som skifter fra natriumphenylbutyrat til RAVICTI, skal have den dosis RAVICTI, som indeholder samme mængde phenylbutansyre.
English: Oral administration of glycerol phenylbutyrate during the period of organogenesis in rats and rabbits had no effects on embryo-foetal development at 2.7 and 1.9 times the dose in adult patients, respectively.
Danish: Oral administration af glycerolphenylbutyrat til rotter og kaniner i organogeneseperioden påvirkede ikke den embryoføtale udvikling ved hhv. 2,7 og 1,9 gange dosen givet til voksne patienter.
English: Decreased appetite, increased appetite Uncommon Hypoalbuminaemia, hypokalaemia
Danish: Almindelig Appetitløshed, øget appetit Ikke almindelig Hypoalbuminæmi, hypokaliæmi
English: If spot U-PAGN concentrations fall below these levels, assess compliance with medicinal product and/or effectiveness of medicinal product administration (e.g., via feeding tube) and consider increasing the glycerol phenylbutyrate dose in compliant patients to achieve optimal ammonia control (within normal limit for patients under 2 years of age and less than half ULN in older patients when fasted).
Danish: Hvis spot-U-PAGN-koncentrationer falder til under disse niveauer, skal komplians og/eller effektiviteten af administrationen af lægemidlet (f.eks. via sonde) vurderes, og det skal overvejes at øge glycerolphenylbutyrat-dosis hos patienter, som overholder behandlingen, for at opnå maksimal kontrol af ammoniak (inden for normalgrænsen for patienter under 2 år og under halvdelen af ULN hos ældre patienter ved faste).
English: Discard the oral syringe after the last dose of the day.
Danish: Kassér den orale sprøjte efter dagens sidste dosis.
English: However, maternal toxicity and adverse effects on embryo-foetal development including reduced foetal weights and cervical ribs were observed in a rat study with a dose approximately 6 times the dose in adult patients, based on combined AUCs for PBA and PAA.
Danish: Maternel toksicitet og skadelige virkninger på den embryoføtale udvikling, herunder reduceret fostervægt og cervikale ribben, blev dog set i et rottestudie med en dosis på ca. 6 gange dosen givet til voksne patienter baseret på kombinerede AUC'er for PBA og PAA.
English: Do not drive or use machines whilst experiencing these side effects.
Danish: Undlad at føre motorkøretøj og betjene maskiner, hvis du har disse bivirkninger.
English: The most frequently reported adverse reactions (>5%) during glycerol phenylbutyrate treatment were diarrhoea, flatulence, and headache (8.8% each); decreased appetite (7.0%), vomiting (6.1%); and fatigue, nausea and, skin odour abnormal (5.3% each).
Danish: Den hyppigst rapporterede bivirkning (>5 %) under behandling med glycerolphenylbutyrat var diarré, flatulens og hovedpine (8,8 % hver), appetitløshed (7,0 %), opkastning (6,1 %) samt træthed, kvalme og unormal lugt fra huden (5,3 % hver).
English: The upper bound of the one-sided 95% CI for the largest placeboadjusted, baseline-corrected QTc, based on individual correction method (QTcI) for glycerol phenylbutyrate, was below 10 ms, demonstrating that glycerol phenylbutyrate had no QT/QTc prolonging effect.
Danish: Den øvre grænse for det ensidede 95 % KI for det længste placebo-justerede, baseline-korrigerede QTc, baseret på en individuel korrektionsmetode (QTcI), for glycerolphenylbutyrat var under 10 ms, hvilket påviste, at glycerolphenylbutyrat ikke har nogen QT/QTc forlængende effekt.
English: In a juvenile rat study with daily oral dosing performed on postpartum day 2 through mating and pregnancy after maturation, terminal body weight was dose-dependently reduced in males and females, by up to 16% and 12% respectively.
Danish: I et rottestudie med unge dyr med daglig oral dosering fra dag 2 postpartum gennem parring og drægtighed efter kønsmodning var den terminale legemsvægt reduceret dosisafhængigt hos hanner og hunner med hhv. 16 % og 12 %.
English: The dose of glycerol phenylbutyrate should be adjusted to produce a fasting plasma ammonia level that is less than half the upper limit of normal (ULN) in patients 6 years and older.
Danish: Glycerolphenylbutyrat-dosis skal justeres for at opnå et fastende ammoniak-niveau i plasma på under halvdelen af den øvre normalgrænse (ULN) hos patienter på 6 år eller derover.
English: Even while on treatment with glycerol phenylbutyrate, acute hyperammonaemia including hyperammonaemic encephalopathy may occur in a proportion of patients.
Danish: Selv under behandling med glycerolphenylbutyrat kan akut hyperammoniæmi, herunder hyperammoniæmisk encefalopati, forekomme hos en del af patienterne.
English: Amino acid level decreased Gamma-glutamyltransferase increased Hepatic enzyme increased Transaminases increased
Danish: Nedsat aminosyreniveau Forhøjet gamma-glutamyltransferase Forhøjede leverenzymer Forhøjede transaminaser
English: The reclosable bottle cap should be discarded when the bottle is empty or after 14 days following opening even if the bottle is not empty.
Danish: Det lukbare adapter skal kasseres, når flasken er tom, og flasken skal kasseres 14 dage efter, den er åbnet, selv hvis den ikke er tom.
English: • through a tube that goes through your nose to the stomach - called a ‘nasogastric tube'
Danish: • gennem en sonde i næsen, som går gennem næsen til mavesækken - kaldet en nasogastrisk sonde
English: Tap the oral syringe to remove air bubbles, making sure you have filled it with the correct amount of liquid.
Danish: Slå let på sprøjten for at fjerne luftbobler og vær sikker på, at du har fyldt den med den rigtige mængde væske.
English: For patients who can swallow liquids take RAVICTI should be taken orally, even those with a nasogastric and/or gastrostomy tube.
Danish: For patienter, som kan synke væsker, skal RAVICTI tages oralt selv for patienter med en nasogastrisk og/eller gastrostomisonde.
English: Therefore, dosage for adult and paediatric patients with mild, moderate or severe hepatic impairment should be started at the lower end of the recommended dosing range (4.5 ml/m2/day) and kept at the lowest dose necessary to control the patient's ammonia levels.
Danish: Dosering af voksne og pædiatriske patienter med let, moderat eller svært nedsat leverfunktion skal derfor begynde i den lave ende af det anbefalede dosisinterval (4,5 ml/m2/dag) og holdes på den lavest mulige dosis, som er nødvendig for at regulere patientens ammoniak-niveau.
English: Pharmacotherapeutic group: Other alimentary tract and metabolism products, various alimentary tract and metabolism products ATC code: A16AX09
Danish: Farmakoterapeutisk klassifikation: Andre midler til sygdomme i fordøjelsesorganer og stofskifte, forskellige midler til sygdomme i fordøjelsesorganer og stofskifte, ATC-kode: A16AX09
English: RAVICTI can be added to a small amount of soft foods, such as ketchup, medical formulas, apple sauce or squash puree.
Danish: RAVICTI kan blandes med en lille smule blød mad, såsom ketchup, ernæringspræparat, æblemos eller græskarmos.
English: The medicinal product may be mixed with medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) and used within 2 hours when stored at 25° C, or up to 24 hours, refrigerated.
Danish: Lægemidlet kan blandes med ernæringspræparater (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree og Citrullin), og blandingen skal anvendes inden for 2 timer ved opbevaring ved 25° C eller inden for 24 timer ved opbevaring i køleskab.
English: These findings collectively indicate that conversion of PAA to PAGN may be impaired in patients with severe hepatic impairment and that a plasma PAA to PAGN ratio > 2.5 identifies patients at risk of elevated PAA levels.
Danish: Disse fund angiver tilsammen, at omdannelsen af PAA til PAGN kan være forringet hos patienter med svært nedsat leverfunktion, og at en plasma-PAA:PAGN-ratio > 2,5 identificerer patienter med risiko for forhøjede PAA-niveauer.
English: PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form PAGN, which is excreted by the kidneys.
Danish: PAA konjugerer med glutamin (som indeholder 2 kvælstofmolekyler) via acetylering i leveren og nyrerne og danner PAGN, som udskilles renalt.
English: Take RAVICTI by mouth unless otherwise directed by your doctor.
Danish: Tag RAVICTI oralt, medmindre lægen anviser noget andet.
English: In healthy female volunteers, mean Cmax for PAA was 51% and 120% higher than in male volunteers after administration of 4 ml and 6 ml 3 times daily for 3 days, respectively.
Danish: Hos raske frivillige kvinder var den gennemsnitlig Cmax for PAA 51 % og 120 % højere end hos frivillige mænd efter administration af hhv. 4 ml og 6 ml 3 gange dagligt i 3 dage.
English: Effects of glycerol phenylbutyrate on other CYP isoenzymes have not been studied in humans and cannot be excluded.
Danish: Glycerolphenylbutyrats indvirkning på andre CYP-isoenzymer er ikke blevet undersøgt hos mennesker, og en indvirkning kan ikke udelukkes.
English: • 9000 microgram (mcg/ml) for patients under 2 years of age
Danish: • 9.000 mikrogram/ml for patienter under 2 år
English: If you forget to take RAVICTI
Danish: Hvis du har glemt at tage RAVICTI
English: • The active substance is glycerol phenylbutyrate.
Danish: • Aktivt stof: glycerolphenylbutyrat.
English: No studies were conducted in UCD patients with renal impairment; the safety of glycerol phenylbutyrate in patients with renal impairment is unknown.
Danish: Der er ikke blevet udført studier hos UCD-patienter med nedsat nyrefunktion, og sikkerheden af glycerolphenylbutyrat hos patienter med nedsat nyrefunktion kendes ikke.
English: Pregnancy, contraception and breast-feeding
Danish: Graviditet, kontraception og amning
English: Reversible clinical manifestations suggestive of neurotoxicity (e.g., nausea, vomiting, somnolence) have been reportedly associated with phenylacetate levels ranging from 499-1285 mcg/ml in cancer patients who received PAA intravenously.
Danish: Reversible kliniske manifestationer, som antyder neurotoksicitet (f.eks. kvalme, opkastning, døsighed), er blevet forbundet med phenylacetatniveauer fra 499-1.285 mikrogram/ml hos cancerpatienter, som fik PAA intravenøst.
English: No PAA toxicity was observed in the subjects age < 2 months.
Danish: Der blev ikke observeret PAAtoksicitet hos forsøgsdeltagere < 2 måneder.
English: • decreased or increased appetite, not wanting to eat some foods
Danish: • appetitløshed eller øget appetit, madlede over for visse fødemidler
English: In vivo exposure to glycerol phenylbutyrate has resulted in decreased systemic exposure to midazolam of approximately 32% and increased exposure to the 1-hydroxy metabolite of midazolam, suggesting that steady-state dosing of glycerol phenylbutyrate results in CYP3A4 induction.
Danish: In vivo eksponering for glycerolphenylbutyrat har resulteret i reduceret systemisk eksponering for midazolam på cirka 32 % og øget eksponering for 1-hydroxy-metabolitten af midazolam, hvilket indikerer, at steady state dosering af glycerolphenylbutyrat resulterer i CYP3A4induktion.
English: All patients successfully transitioned to RAVICTI within 3 days, where successful transition was defined as no signs and symptoms of hyperammonemia and a venous ammonia value less than 100 micromol/L.
Danish: Alle patienter overgik til RAVICTI vellykket i løbet af 3 dage, hvor en vellykket overgang blev defineret som ingen tegn og symptomer på hyperammoniæmi og en venøs ammoniakværdi på under 100 mikromol/l.
English: Tabulated list of adverse reactions The adverse reactions are listed below, by system organ class and by frequency.
Danish: Bivirkningerne i nedenstående tabel er angivet efter systemorganklasse og hyppighed.
English: In a rat study, glycerol phenylbutyrate caused a statistically significant increase in the incidence of pancreatic acinar cell adenoma, carcinoma, and combined adenoma or carcinoma in males and females, at a dose of 4.7 and 8.4 times the dose in adult patients, (6.87 ml/m2/day based on combined AUCs for PBA and PAA).
Danish: I et rottestudie forårsagede glycerolphenylbutyrat en statistisk signifikant stigning i forekomsten af pankreatisk acinic cell adenom, karcinom og kombineret adenom eller karcinom hos han- og hunrotter ved en dosis på 4,7 og 8,4 gange dosen givet til voksne patienter (6,87 ml/m2/dag baseret på kombinerede AUC'er for PBA og PAA).
English: Open-Label, Uncontrolled, Extension Studies in Paediatric Patients Long-term (12-month), uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonaemic crisis over a 12-month period in three studies (Study 2, which also enrolled adults, and extensions of Studies 3 and 4).
Danish: Åbne, ukontrollerede forlængelsesstudier hos pædiatriske patienter Langvarige (12-måneders), ukontrollerede, åbne studier blev udført for at vurdere månedlig ammoniakkontrol og hyperammoniæmisk krise i løbet af en periode på 12 måneder i tre studier (studie 2, som også inkluderede voksne, og forlængelser af studie 3 og 4).
English: The mean (SD) percentage of administered PBA eliminated as PAGN was approximately 68.9% (17.2) in adults and 66.4% (23.9) in paediatric UCD patients at steady state.
Danish: Ved steady state elimineredes gennemsnitligt (SD) ca. 68,9 % (17,2) af det administrerede PBA som PAGN hos voksne og 66,4 % (23,9) hos pædiatriske patienter med UCD.
English: Glycerol phenylbutyrate was found to be non-inferior to sodium phenylbutyrate with respect to ammonia control in both of these paediatric studies.
Danish: Glycerolphenylbutyrat blev fundet at være non-inferiort i forhold til natriumphenylbutyrat med hensyn til kontrol af ammoniak i begge disse pædiatriske forsøg.
English: Of the 45 paediatric patients participating in the open-label treatment with glycerol phenylbutyrate, 11 patients (24%) reported a total of 22 hyperammonemic crises.
Danish: Ud af de 45 pædiatriske patienter, som deltog i den åbne behandling med glycerolphenylbutyrat, rapporterede 11 patienter (24 %) i alt 22 hyperammoniæmiske kriser.
English: Women of childbearing potential/contraception in males and females The use of RAVICTI in women of childbearing potential must be accompanied by the use of effective contraception (see section 4.4).
Danish: Kvinder i den fertile alder/kontraception hos mænd og kvinder Brug af RAVICTI hos kvinder i den fertile alder skal ledsages af brug af effektiv kontraception (se pkt.
English: Nine patients successfully transitioned to RAVICTI within 4 days, followed by 3 days of observation for a total of 7 days, where successful transition was defined as no signs and symptoms of hyperammonemia and a venous ammonia value less than 100 micromol/L.
Danish: Ni patienter overgik vellykket til RAVICTI i løbet af 4 dage, efterfulgt af 3 dage under observation (i alt 7 dage), hvor vellykket overgang blev defineret som ingen tegn og symptomer på hyperammoniæmi og en venøs ammoniakværdi på under 100 mikromol/l.
English: The effect of multiple doses of glycerol phenylbutyrate 13.2 g/day and 19.8 g/day (approximately 69% and 104% of the maximum recommended daily dosage) on QTc interval was evaluated in a randomised, placebo- and active-controlled (moxifloxacin 400 mg), four-treatment-arm, crossover study in 57 healthy subjects.
Danish: Virkningen af flere doser glycerolphenylbutyrat 13,2 g/dag og 19,8 g/dag (cirka 69 % og 104 % af den maksimale anbefalede daglige dosis) på QTc-intervallet blev evalueret hos 57 raske forsøgspersoner i et randomiseret placebo- og aktivt kontrolleret (moxifloxacin 400 mg) overkrydsningsstudier med fire behandlingsgrupper.
English: RAVICTI may have major influence on the ability to drive and use machines given that treatment with glycerol phenylbutyrate may cause dizziness or headaches (see section 4.8).
Danish: RAVICTI kan i væsentlig grad påvirke evnen til at føre motorkøretøj og betjene maskiner, da behandling med glycerolphenylbutyrat kan forårsage svimmelhed eller hovedpine (se pkt.
English: Compatibility studies have demonstrated glycerol phenylbutyrate chemical and physical in-use stability with the following foods and nutritional supplements: apple sauce, ketchup, squash puree, and five medical formulas (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose, Pro Phree and Citrulline) typically consumed by UCD patients (see section 4.2).
Danish: Forligelighedsstudier har påvist, at glycerolphenylbutyrat er kemisk og fysisk stabilt under anvendelse med følgende fødevarer og kosttilskud: æblemos, ketchup, græskarmos og fem ernæringspræparater (Cyclinex-1, Cyclinex-2, UCD-1, UCD-2, Polycose , Pro Phree og citrullin), som typisk bruges af UCD-patienter (se pkt.
English: Uncommon Hypothyroidism
Danish: Ikke almindelig Hypotyroidisme
English: In healthy subjects, the systemic exposure to PAA, PBA, and PAGN increased in a dose dependent manner.
Danish: Hos raske forsøgspersoner steg den systemiske eksponering for PAA, PBA og PAGN dosisafhængigt.
English: The mean peak ratio of PAA to PAGN in UCD patients aged birth to less than 2 months was higher (mean: 1.65; range 0.14 to 7.07) than for UCD patients aged 2 months to less than 2 years (mean 0.59; range 0.17 to 1.21).
Danish: Den gennemsnitlige ratio mellem peak af PAA og peak af PAGN hos UCD-patienter fra fødslen til under 2 måneder var højere (gennemsnit: 1,65, interval 0,14-7,07) end hos UCD-patienter i alderen 2 måneder til under 2 år (gennemsnit 0,59, interval 0,17-1,21).
English: If symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses, measure plasma PAA and plasma PAA to PAGN and consider reduction of glycerol phenylbutyrate dosage or increase the frequency of dosing if the PAA level exceeds 500 mcg/L and the plasma PAA to PAGN ratio exceeds 2.5.
Danish: Hvis symptomerne opkastning, kvalme, hovedpine, døsighed, forvirring eller søvnløshed er til stede uden et højt ammoniakniveau eller andre interkurrente sygdomme, skal plasma-PAA og plasmaPAA:PAGN-ratio måles, og det skal overvejes at reducere dosis af glycerolphenylbutyrat eller øge doseringshyppigheden, hvis PAA-niveauet overstiger 500 mikrogram/l, og plasma-PAA:PAGNratioen overstiger 2,5.
English: Population pharmacokinetic modelling and dosing simulations suggest that PBA enters the circulation about 70-75% more slowly when given orally as glycerol phenylbutyrate as compared with sodium phenylbutyrate and further indicate that body surface area is the most significant covariate explaining the variability of PAA clearance.
Danish: Populationsfarmakokinetisk modellering og dosissimuleringer antyder, at PBA optages i kredsløbet ca. 70-75 % langsommere, når det gives oralt som glycerolphenylbutyrat sammenlignet med natriumphenylbutyrat, og indikerer endvidere, at kropoverfladearealet er den mest signifikante kovariat til at forklare variabiliteten i PAA-clearance.
English: • feeling sleepy, tired, light-headed or sometimes confused
Danish: • døsighed, træthed, uklarhed eller undertiden forvirring
English: Glycerol phenylbutyrate and/or its metabolites, PAA and PBA, have been shown to be weak inducers of CYP3A4 enzyme in vivo.
Danish: Det er vist, at glycerolphenylbutyrat og/eller dets metabolitter, PAA og PBA er svage CYP3A4induktorer in vivo.
English: Because conversion of PAA to PAGN occurs in the liver, patients with severe hepatic impairment may have reduced conversion capability and higher plasma PAA and plasma PAA to PAGN ratio.
Danish: Da PAA omdannes til PAGN i leveren, kan patienter med svært nedsat leverfunktion have en reduceret konverteringsevne og højere plasma-PAA og plasma-PAA:PAGN-ratio.
English: The same oral syringe should be used for all doses taken each day.
Danish: Den samme sprøjte skal bruges til alle doser samme dag.
English: It is not recommended to administer a dose of 0.5 ml or less with nasogastric, gastrostomy or nasojejunal tubes, given the low drug recovery in dosing.
Danish: Det anbefales ikke at administrere en dosis på 0,5 ml eller derunder med en nasogastrisk, nasojejunal eller gastrostomisonde på grund af den lave genfinding af lægemidlet ved denne dosis.
English: In such cases, increasing the dosing frequency may result in a lower plasma PAA level and PAA to PAGN ratio.
Danish: I sådanne tilfælde kan hyppigere dosering resultere i et lavere PAA-plasmaniveau og en lavere PAA:PAGN-ratio.
English: In vitro studies evaluating the percent recovery of total dose delivered with nasogastric or gastrostomy tubes demonstrated the percent of dose recovered was >99% for doses > 1 ml and 70% for a 0.5 ml dose.
Danish: In vitro studier til evaluering af den procentvise genfinding af den samlede dosis leveret gennem en nasogastrisk, nasojejunal eller gastrostomisonde påviste, at procentdelen af dosen genvundet var >99 % for doser >1 ml og 70 % for en dosis på 0,5 ml.
English: Fatigue, oedema peripheral Uncommon Hunger, Pyrexia
Danish: Almindelig Træthed, perifert ødem Ikke almindelig Sult, pyreksi
English: Hypophagia
Danish: Hypofagi
English: In healthy subjects, after administration of 4 ml, 6 ml, and 9 ml 3 times daily for 3 days, the ratio of mean AUC0-23h of PAA to PAGN was 1, 1.25, and 1.6, respectively.
Danish: Efter administration af 4 ml, 6 ml og 9 ml 3 gange dagligt i 3 dage til raske forsøgspersoner var forholdet mellem gennemsnitlig AUC0-23t af PAA og PAGN hhv. 1, 1,25 og 1,6.
English: Therefore, measurement of plasma PAA and PAGN levels may be useful to guide dosing.
Danish: Måling af PAA og PAGN i plasma kan derfor være nyttig i forbindelse med dosisbestemmelse.
English: In in vitro studies, the specific activity of lipases for glycerol phenylbutyrate was seen in the following decreasing order: pancreatic triglyceride lipase, carboxyl ester lipase, and pancreatic lipase-related protein 2.
Danish: I in vitro studier aftog den specifikke aktivitet af lipaser, der hydrolyserer glycerolphenylbutyrat, i følgende rækkefølge: pancreas-triglyceridlipase, carboxylester-lipase, og pancreaslipase-relateret protein 2.
English: The product contains no excipients.
Danish: Præparatet indeholder ikke hjælpestoffer.
English: Adverse reactions reported in more paediatric than adult patients during long-term treatment with glycerol phenylbutyrate included upper abdominal pain (3 of 49 paediatric [6.1%] versus 1 of 51 adults [2.0%] and increased anion gap (2 of 49 paediatric [4.1%] versus 0 of 51 adults [0%].
Danish: Bivirkninger rapporteret hyppigere hos pædiatriske end voksne patienter ved langvarig behandling med glycerolphenylbutyrat inkluderede øvre abdominalsmerter (3 ud af 49 børn [6,1 %] og 1 ud af 51 voksne [2,0 %]) og forhøjet anion-gap (2 ud af 49 børn [4,1 %] og 0 ud af 51 voksne [0 %]).
English: After the last dose of the day, the oral syringe should be discarded.
Danish: Efter dagens sidste dosis skal den orale sprøjte kasseres.
English: PBA derived from glycerol phenylbutyrate is further converted by β-oxidation to PAA.
Danish: PBA dannet fra glycerolphenylbutyrat omdannes yderligere til PAA ved β-oxidation.
English: Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of glycerol phenylbutyrate and/or absorption of phenylbutyrate and reduced control of plasma ammonia.
Danish: Lave niveauer af eller manglende pancreasenzymer eller tarmsygdom, der medfører malabsorption af fedt, kan resultere i reduceret eller manglende hydrolyse af glycerolphenylbutyrat og/eller absorption af phenylbutyrat og i reduceret kontrol med ammoniak i plasma.
English: Herefordshire
Danish: Herfordshire
English: Glycerol phenylbutyrate is a nitrogen-binding medicinal product.
Danish: Glycerolphenylbutyrat er et kvælstofbindende lægemiddel.
English: Constipation, Flatulence, Gastrooesophageal reflux disease
Danish: Forstoppelse, flatulens, gastroøsofageal reflukssygdom
English: Study in Children Less Than 2 Months of Age
Danish: Studie med børn under 2 måneder